Scott N. Holden

4.7k total citations · 1 hit paper
44 papers, 3.7k citations indexed

About

Scott N. Holden is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Scott N. Holden has authored 44 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 18 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Scott N. Holden's work include Cancer Treatment and Pharmacology (16 papers), HER2/EGFR in Cancer Research (11 papers) and Colorectal Cancer Treatments and Studies (10 papers). Scott N. Holden is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), HER2/EGFR in Cancer Research (11 papers) and Colorectal Cancer Treatments and Studies (10 papers). Scott N. Holden collaborates with scholars based in United States, United Kingdom and Australia. Scott N. Holden's co-authors include Eric Holmgren, Fairooz F. Kabbinavar, Hartmut Koeppen, Adrian M. Jubb, Herbert I. Hurwitz, H. Hurwitz, Jamey Skillings, Frank A. Scappaticci, Emily K. Bergsland and Howard A. Burris and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and JNCI Journal of the National Cancer Institute.

In The Last Decade

Scott N. Holden

43 papers receiving 3.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab

2007 725 citations Scott N. Holden, Fairooz F. Kabbinavar et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott N. Holden United States	23	2.2k	1.3k	860	823	424	44	3.7k
James L. Speyer United States	37	2.2k 1.0×	928 0.7×	788 0.9×	363 0.4×	291 0.7×	94	4.4k
Robert Justice United States	40	2.5k 1.1×	2.8k 2.1×	1.7k 2.0×	465 0.6×	871 2.1×	61	6.4k
Ferry A.L.M. Eskens Netherlands	43	2.9k 1.3×	2.6k 2.0×	1.5k 1.7×	518 0.6×	1.2k 2.9×	161	6.4k
Susan Galbraith United States	23	1.1k 0.5×	957 0.7×	523 0.6×	696 0.8×	610 1.4×	45	2.9k
Chiara Carlomagno Italy	29	3.4k 1.5×	1.0k 0.8×	1.1k 1.3×	508 0.6×	1.2k 2.8×	99	4.7k
Yong Sang Hong South Korea	33	3.5k 1.6×	834 0.6×	1.3k 1.5×	313 0.4×	488 1.2×	208	4.8k
Beth Overmoyer United States	33	4.4k 2.0×	1.5k 1.2×	1.3k 1.5×	884 1.1×	1.9k 4.5×	143	6.2k
Roberto Iacovelli Italy	34	2.1k 0.9×	1.5k 1.2×	2.6k 3.0×	395 0.5×	1.2k 2.9×	224	4.6k
Albert Abad Spain	28	2.5k 1.1×	1.2k 0.9×	1.6k 1.9×	180 0.2×	565 1.3×	84	4.2k
Sergio Ricci Italy	25	2.7k 1.2×	971 0.7×	1.2k 1.4×	270 0.3×	592 1.4×	62	5.5k

Countries citing papers authored by Scott N. Holden

Since Specialization

Citations

This map shows the geographic impact of Scott N. Holden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott N. Holden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott N. Holden more than expected).

Fields of papers citing papers by Scott N. Holden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott N. Holden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott N. Holden. The network helps show where Scott N. Holden may publish in the future.

Co-authorship network of co-authors of Scott N. Holden

This figure shows the co-authorship network connecting the top 25 collaborators of Scott N. Holden. A scholar is included among the top collaborators of Scott N. Holden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott N. Holden. Scott N. Holden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Crawley, Danielle, Eleni Karapanagiotou, Scott N. Holden, et al.. (2020). Psychological experiences in patients with lung cancer taking targeted therapies. Lung Cancer. 139. S82–S83. 1 indexed citations

Bie, Jessie De, Annelies Verlaet, Irmgard Immig, et al.. (2014). Submitted oral presentations. Advances in Animal Biosciences. 5(2). 247–255. 3 indexed citations

Ware, Joseph A., Jin Y. Jin, Laurent Salphati, et al.. (2013). Impact of Food and the Proton Pump Inhibitor Rabeprazole on the Pharmacokinetics of GDC-0941 in Healthy Volunteers: Bench to Bedside Investigation of pH-Dependent Solubility. Molecular Pharmaceutics. 10(11). 4074–4081. 16 indexed citations

Beeram, Muralidhar, Ian E. Krop, Howard A. Burris, et al.. (2012). A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer. Cancer. 118(23). 5733–5740. 74 indexed citations

Girish, Sandhya, Manish Gupta, Bei Wang, et al.. (2012). Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemotherapy and Pharmacology. 69(5). 1229–1240. 198 indexed citations

Budha, Nageshwar, Adam Frymoyer, Mark J. Dresser, et al.. (2012). Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?. Clinical Pharmacology & Therapeutics. 92(2). 203–213. 271 indexed citations

Hidalgo, Manuel, Antonio Calles, Dejan Juric, et al.. (2012). Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors.. Journal of Clinical Oncology. 30(15_suppl). 2567–2567. 1 indexed citations

Burris, Howard A., Jay Tibbitts, Scott N. Holden, Mark X. Sliwkowski, & Gail D. Lewis Phillips. (2011). Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer. Clinical Breast Cancer. 11(5). 275–282. 90 indexed citations

Krop, Ian E., Muralidhar Beeram, Shanu Modi, et al.. (2010). Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 28(16). 2698–2704. 437 indexed citations

10.

Denlinger, Crystal S., Rebecca Blanchard, Lu Xu, et al.. (2009). Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 65(1). 97–105. 21 indexed citations

11.

Lam, Elaine T., Cindy L. O’Bryant, M. Basche, et al.. (2008). A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Molecular Cancer Therapeutics. 7(12). 3685–3694. 6 indexed citations

12.

Camidge, D. Ross, S. Gail Eckhardt, Lia Gore, et al.. (2008). A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anti-Cancer Drugs. 19(1). 77–84. 23 indexed citations

13.

Chow, Laura Q.M., Daniel L. Gustafson, Cindy L. O’Bryant, et al.. (2008). A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 63(1). 65–74. 19 indexed citations

14.

Holden, Scott N., Sabine Eckhardt, R. Basser, et al.. (2005). Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Annals of Oncology. 16(8). 1391–1397. 247 indexed citations

15.

Kobayashi, Hiroyuki, S. Gail Eckhardt, Jennifer A. Lockridge, et al.. (2005). Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 56(4). 329–336. 28 indexed citations

16.

Ince, William L., Adrian M. Jubb, Scott N. Holden, et al.. (2005). Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab. JNCI Journal of the National Cancer Institute. 97(13). 981–989. 262 indexed citations

17.

Jubb, Adrian M., Herbert I. Hurwitz, Wei Bai, et al.. (2005). Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer. Journal of Clinical Oncology. 24(2). 217–227. 305 indexed citations

18.

Herbst, Roy S., et al.. (2002). Angiogenesis inhibitors in clinical development for lung cancer. Seminars in Oncology. 29(1). 66–77. 37 indexed citations

19.

Eder, J. P., et al.. (1991). Elevated topoisomerase ii top ii levels in alkylating agent aa resistant breast cancer. 32. 349. 2 indexed citations

20.

Vargas, Socorro J., Scott N. Holden, Pamela Fall, & Lawrence G. Raisz. (1989). Effects Of Atrial Natriuretic Factor on Cyclic Nucleotides, Bone Resorption, Collagen and Deoxyribonucleic Acid Synthesis, and Prostaglandin E₂Production in Fetal Rat Bone Cultures*. Endocrinology. 125(5). 2527–2531. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact